Harnessing histone deacetylase inhibitors for enhanced cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• Cancer often suppresses the immune response, aiding tumor growth and metastasis.
• Reactivating the immune system against cancer offers significant therapeutic potential.
• Histone deacetylase inhibitors (HDACis) are a class of targeted therapies modulating immune responses through epigenetic modifications.

Purpose of the Study:

• To review how different classes of HDACis impact the immune system.
• To explore recent advancements in combining HDACis with novel immunotherapies.
• To summarize findings from in vitro, in vivo, and clinical studies.

Main Methods:

• Literature review of in vitro, in vivo, and clinical studies on HDACis and cancer immunotherapy.
• Analysis of the mechanisms by which HDACis influence anti-cancer immune responses.
• Examination of emerging combination strategies involving HDACis and immunotherapies.

Main Results:

• HDACis can enhance cancer treatment efficacy by relaxing chromatin, improving DNA accessibility.
• These inhibitors can disrupt cancer DNA repair mechanisms and upregulate immune checkpoint receptors.
• Evidence suggests HDACis modulate various immune cell functions relevant to anti-tumor activity.

Conclusions:

• HDACis represent a promising epigenetic strategy to enhance anti-cancer immunity.
• Combining HDACis with immunotherapy holds potential for improved antitumor outcomes.
• Further research into HDACi and immunotherapy combinations may overcome treatment resistance.